StockData

Elutia vs LENZ Therapeutics

ELUT and LENZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELUT and LENZ compare

LENZ Therapeutics is the larger company, worth 2.9 times as much as Elutia ($110M against $37.8M).

LENZ Therapeutics grew revenue faster over the last twelve months (330% versus −0.34% for Elutia).

Elutia keeps more of each dollar of sales as profit, with a net margin of 427% compared with −587% at LENZ Therapeutics.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELUTLENZ
Size and price
Market cap$37.8M$110M
Share price$0.854$3.50
Change, 1 year14.5%−86.3%
Change, 5 years−83.6%−94.8%
Beta (5Y)0.372.27
Employees26152
StockData Score
Total score99
Valuation score13 (better)
Growth score11
Performance score2 (better)0
Health score55
Dividend score00
Valuation
P/S3.1× (better)5.1×
P/B2.4×0.5× (better)
FCF yield−122%−104% (better)
Fair value$0.913$7.86
Margin of safety6.5%55.5% (better)
Growth
Revenue growth (TTM)−0.34%330% (better)
Revenue growth, 5Y average−22.0%–
Profitability
Gross margin57.8%–
Operating margin−215% (better)−632%
Net margin427% (better)−587%
FCF margin−379% (better)−533%
Return on equity–−59.2%
Financial health
Debt / equity0.000.00
Current ratio1.7713.55 (better)
Altman Z-score−6.571.32 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.8%110%
Held by insiders52.0%6.7%
Insider net buying, 12 months$212K (better)−$8.8M
Short interest, % of float0.16%24.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.